Search

Your search keyword '"Curto S"' showing total 163 results
Start Over Author "Curto S"
163 results on '"Curto S"'

2. Corrigendum: The silent epidemic of diabetic ketoacidosis at diagnosis of type 1 diabetes in children and adolescents in italy during the covid-19 pandemic in 2020(Front. Endocrinol., (2022), 13, (878634), 10.3389/fendo.2022.878634)

Author

Cherubini, V., Marino, M., Scaramuzza, A. E., Tiberi, V., Bobbio, A., Delvecchio, M., Piccinno, E., Ortolani, F., Innaurato, S., Felappi, B., Gallo, F., Ripoli, C., Ricciardi, M. R., Pascarella, F., Stamati, F. A., Citriniti, F., Arnaldi, C., Monti, S., Graziani, V., De Berardinis, F., Giannini, C., Chiarelli, F., Zampolli, M., De Marco, R., Bracciolini, G. P., Grosso, C., De Donno, V., Piccini, B., Toni, S., Coccioli, S., Cardinale, G., Bassi, M., Minuto, N., D?annunzio, G., Maffeis, C., Marigliano, M., Zanfardino, A., Iafusco, D., Rollato, A. S., Piscopo, A., Curto, S., Lombardo, F., Bombaci, B., Sordelli, S., Mameli, C., Macedoni, M., Rigamonti, A., Bonfanti, R., Frontino, G., Predieri, B., Bruzzi, P., Mozzillo, E., Rosanio, F., Franzese, A., Piredda, G., Cardella, F., Iovane, B., Calcaterra, V., Berioli, M. G., Lasagni, A., Pampanini, V., Patera, P. I., Schiaffini, R., Rutigliano, I., Meloni, G., De Sanctis, L., Tinti, D., Trada, M., Guerraggio, L. P., Franceschi, R., Cauvin, V., Tornese, G., Franco, F., Musolino, G., Maltoni, G., Talarico, V., Iannilli, A., Lenzi, L., Matteoli, M. C., Pozzi, E., Moretti, C., Zucchini, S., Rabbone, I., Gesuita, R., Cherubini, V., Marino, M., Scaramuzza, A. E., Tiberi, V., Bobbio, A., Delvecchio, M., Piccinno, E., Ortolani, F., Innaurato, S., Felappi, B., Gallo, F., Ripoli, C., Ricciardi, M. R., Pascarella, F., Stamati, F. A., Citriniti, F., Arnaldi, C., Monti, S., Graziani, V., De Berardinis, F., Giannini, C., Chiarelli, F., Zampolli, M., De Marco, R., Bracciolini, G. P., Grosso, C., De Donno, V., Piccini, B., Toni, S., Coccioli, S., Cardinale, G., Bassi, M., Minuto, N., D'Annunzio, G., Maffeis, C., Marigliano, M., Zanfardino, A., Iafusco, D., Rollato, A. S., Piscopo, A., Curto, S., Lombardo, F., Bombaci, B., Sordelli, S., Mameli, C., Macedoni, M., Rigamonti, A., Bonfanti, R., Frontino, G., Predieri, B., Bruzzi, P., Mozzillo, E., Rosanio, F., Franzese, A., Piredda, G., Cardella, F., Iovane, B., Calcaterra, V., Berioli, M. G., Lasagni, A., Pampanini, V., Patera, P. I., Schiaffini, R., Rutigliano, I., Meloni, G., De Sanctis, L., Tinti, D., Trada, M., Guerraggio, L. P., Franceschi, R., Cauvin, V., Tornese, G., Franco, F., Musolino, G., Maltoni, G., Talarico, V., Iannilli, A., Lenzi, L., Matteoli, M. C., Pozzi, E., Moretti, C., Zucchini, S., Rabbone, I., and Gesuita, R.

Subjects
socioeconomic status, COVID - 19, type 1 diabetes, DKA, socioeconomic statu, diabetes onset
Abstract

In the published article, there was an error in affiliation(s) 29. Instead of “Departement of Pediatrics, Diabetes Research Institute, IRCCS San Raffaele, Milano, Italy”, it should be “Diabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Published
2022

6. Campylobacter jejuni bacteremia in Italian pediatric patients with acute lymphoblastic leukemia: Report of two cases

Author

Martora F., Pagliuca C., Della Pepa M. E., Della Rocca M. T., Curto S., Iovene M. R., Vitiello M., Martora, F., Pagliuca, C., Della Pepa, M. E., Della Rocca, M. T., Curto, S., Iovene, M. R., and Vitiello, M.

Subjects
Campylobacter jejuni, acute lymphoblastic leukemia (ALL), bacteremia
Abstract

Infections caused by Campylobacter jejuni are rarely associated with extraintestinal complications. C. jejuni bacteremia is difficult to detect in patients with hematological malignancies undergoing chemotherapy where the choice of appropriate antibiotic treatment is extremely important. We report two cases of C. jejuni bacteremia in Italian pediatric patients affected by acute lymphoblastic leukemia (ALL). Agreeing with the most recent epidemiological data, both clinical isolates showed a typical phenotypic antimicrobial resistance patterns with combined resistance to ciprofloxacin and tetracycline. To our knowledge, this is the first report of C. jejuni isolation from the blood of ALL pediatric patients in Italy, and it provides important epidemiological information on this rare infection.

Published
2020

10. ESHO benchmarks for computational modeling and optimization in hyperthermia therapy

Author

Paulides, M.M. (Maarten), Rodrigues, D.B. (Dario B.), Bellizzi, G.G. (Gennaro G.), Sumser, K. (Kemal), Curto, S. (Sergio), Neufeld, E., Montanaro, H. (Hazael), Kok, H.P., Dobsicek Trefna, H. (Hana), Paulides, M.M. (Maarten), Rodrigues, D.B. (Dario B.), Bellizzi, G.G. (Gennaro G.), Sumser, K. (Kemal), Curto, S. (Sergio), Neufeld, E., Montanaro, H. (Hazael), Kok, H.P., and Dobsicek Trefna, H. (Hana)

Abstract

Background: The success of cancer hyperthermia (HT) treatments is strongly dependent on the temperatures achieved in the tumor and healthy tissues as it correlates with treatment efficacy and safety, respectively. Hyperthermia treatment planning (HTP) simulations have become pivotal for treatment optimization due to the possibility for pretreatment planning, optimization and decision making, as well as real-time treatment guidance. Materials and methods: The same computational methods deployed in HTP are also used for in silico studies. These are of great relevance for the development of new HT devices and treatment approaches. To aid this work, 3 D patient models have been recently developed and made available for the HT community. Unfortunately, there is no consensus regarding tissue properties, simulation settings, and benchmark applicators, which significantly influence the clinical relevance of computational outcomes. Results and discussion: Herein, we propose a comprehensive set of applicator benchmarks, efficacy and safety optimization algorithms, simulation settings and clinical parameters, to establish benchmarks for method comparison and code verification, to provide guidance, and in view of the 2021 ESHO Grand Challenge (Details on the ESHO grand challenge on HTP will be provided at https://www.esho.info/). Conclusion: We aim to establish guidelines to promote standardization within the hyperthermia community such that novel approaches can quickly prove their benefit as quickly as possible in cli

Published
2021
Full Text
View/download PDF

11. A multi-institution study: comparison of the heating patterns of five different MR-guided deep hyperthermia systems using an anthropomorphic phantom

Author

Curto, S., Mulder, H.T., Aklan, B., Mils, O., Schmidt, M., Lamprecht, U. (Ulf), Peller, M., Wessalowski, R. (Rüdiger), Lindner, L.H. (Lars), Fietkau, R., Zips, D., Holthe, N. (Netteke) van, Franckena, M. (Martine), Paulides, M.M. (Maarten), Rhoon, G.C. (Gerard) van, Curto, S., Mulder, H.T., Aklan, B., Mils, O., Schmidt, M., Lamprecht, U. (Ulf), Peller, M., Wessalowski, R. (Rüdiger), Lindner, L.H. (Lars), Fietkau, R., Zips, D., Holthe, N. (Netteke) van, Franckena, M. (Martine), Paulides, M.M. (Maarten), and Rhoon, G.C. (Gerard) van

Abstract

Introduction Within the hyperthermia community, consensus exists that clinical outcome of the treatment radiotherapy and/or chemotherapy plus hyperthermia (i.e. elevating tumor temperature to 40 − 44 °C) is related to the applied thermal dose; hence, treatment quality is crucial for the success of prospective multi-institution clinical trials. Currently, applicator quality assurance (QA) measurements are implemented independently at each institution using basic cylindrical phantoms. A multi-institution comparison of heating quality using magnetic resonance thermometry (MRT) and anatomical representative anthropomorphic phantoms provides a unique opportunity to obtain novel QA insights to fa

Published
2020
Full Text
View/download PDF

12. Thermal characterization of phantoms used for quality assurance of deep hyperthermia systems

Author

Farina, L. (Laura), Sumser, K. (Kemal), Rhoon, G.C. (Gerard) van, Curto, S. (Sergio), Farina, L. (Laura), Sumser, K. (Kemal), Rhoon, G.C. (Gerard) van, and Curto, S. (Sergio)

Abstract

Tissue mimicking phantoms are frequently used in hyperthermia applications for device and protocol optimization. Unfortunately, a commonly experienced limitation is that their precise thermal properties are not available. Therefore, in this study, the thermal properties of three currently used QA phantoms for deep hyperthermia are measured with an ‘’off-shelf’’ commercial thermal property analyzer. We have measured averaged values of thermal conductivity (k = 0.59 ± 0.07 Wm−1K−1), volumetric heat capacity (C = 3.85 ± 0.45 MJm−3K−1) and thermal diffusivity (D = 0.16 ± 0.02 mm2s−1). These values are comparable with reported values of internal organs, such as liver, kidney and muscle. In addition, a sensitivity study of the performance of the commercial sensor is conducted. To ensure correct thermal measurements, the sample under test should entirely cover the length of the sensor, and a minimum of 4 mm of material parallel to the sensor in all directions should be guaranteed.

Published
2020
Full Text
View/download PDF

13. Standardization of patient modeling in hyperthermia simulation studies: introducing the Erasmus Virtual Patient Repository

Author

Bellizzi, G.G. (Gennaro), Sumser, K. (Kemal), VilasBoas-Ribeiro, I. (Iva), Curto, S. (Sergio), Drizdal, T., Rhoon, G.C. (Gerard) van, Franckena, M. (Martine), Paulides, M.M. (Maarten), Bellizzi, G.G. (Gennaro), Sumser, K. (Kemal), VilasBoas-Ribeiro, I. (Iva), Curto, S. (Sergio), Drizdal, T., Rhoon, G.C. (Gerard) van, Franckena, M. (Martine), and Paulides, M.M. (Maarten)

Abstract

Purpose: Thermal dose-effect relations have demonstrated that clinical effectiveness of hyperthermia would benefit from more controlled heating of the tumor. Hyperthermia treatment planning (HTP) is a potent tool to study strategies enabling target conformal heating, but its accuracy is affected by patient modeling approximations. Homogeneous phantoms models are being used that do not match the body shape of patients in treatment position and often have unrealistic target volumes. As a consequence, simulation accuracy is affected, and performance comparisons are difficult. The aim of this study is to provide the first step toward standardization of HTP simulation studies in terms of patient modeling by introducing the Erasmus Virtual Patient Repository (EVPR): a virtual patient model database.Methods: Four patients with a tumor in the head and neck or the pelvis region were selected, and corresponding models were created using a clinical segmentation procedure. Using the Erasmus University Medical Center standard procedure, HTP was applied to these models and compared to HTP for commonly used surrogate models.Results: Although this study was aimed at presenting the EVPR database, our study illustrates that there is a non-negligible difference in the predicted SAR patterns between patient models and homogeneous phantom-based surrogate models. We further demonstrate the diff

Published
2020
Full Text
View/download PDF

14. Systematic review of pre-clinical and clinical devices for magnetic resonance-guided radiofrequency hyperthermia

Author

Adibzadeh, F. (Fatemeh), Sumser, K. (Kemal), Curto, S. (Sergio), Yeo, D.T.B. (Desmond T. B.), Shishegar, A.A. (Amir A.), Paulides, M.M. (Maarten), Adibzadeh, F. (Fatemeh), Sumser, K. (Kemal), Curto, S. (Sergio), Yeo, D.T.B. (Desmond T. B.), Shishegar, A.A. (Amir A.), and Paulides, M.M. (Maarten)

Abstract

Clinical trials have demonstrated the therapeutic benefits of adding radiofrequency (RF) hyperthermia (HT) as an adjuvant to radio- and chemotherapy. However, maximum utilization of these benefits is hampered by the current inability to maintain the temperature within the desired range. RF HT treatment quality is usually monitored by invasive temperature sensors, which provide limited data sampling and are prone to infection risks. Magnetic resonance (MR) temperature imaging has been developed to overcome these hurdles by allowing noninvasive 3D temperature monitoring in the target and normal tissues. To exploit this feature, several approaches for inserting the RF heating devices into the MR scanner have been proposed over the years. In this review, we summarize the status quo in MR-guided RF HT devices and analyze trends in these hybrid hardware configurations. In addition, we discuss the various approaches, extract best practices and identify gaps regarding the experimental validation procedures for MR - RF HT, aimed at converging to a common standard in this process.

Published
2020
Full Text
View/download PDF

16. Il monitoraggio, la 'frontiera' per le parassitosi neglette

Author

Ianniello, D, Della Pepa, ME, Rinaldi, L, Maurelli, MP, Pepe, P, Chianese, A, Russo, C, Curto, S, Cringoli, G, Galdiero, M., Società Italiana di Medicina delle Migrazioni (SIMM), Ianniello, D, Della Pepa, Me, Rinaldi, L, Maurelli, Mp, Pepe, P, Chianese, A, Russo, C, Curto, S, Cringoli, G, and Galdiero, M.

Published
2018

17. ß-Borylalkenyl Z- e Isomerization in Rhodium-Mediated Diboration of Nonfunctionalized Internal Alkynes

Author

Galván Curto, S., Esteruelas, M.A., Oliván, M., Oñate, E., and Vélez, A.

Abstract

The elemental steps for the preparation of (E)-pinBC(Me)=C(Me)Bpin (Bpin = pinacolboryl) by means of the anti addition of B2pin2 to 2-butyne, promoted by the boryl complex Rh(Bpin){xant(PiPr2)2} (1; xant(PiPr2)2 = 9, 9-dimethyl-4, 5-bis(diisopropylphosphino)xanthene), have been analyzed from a kinetic point of view, and the intermediates of the process, the ß-borylakenyl complexes Rh{(Z)-C(Me)=C(Me)Bpin}{xant(PiPr2)2} (2) and Rh{(E)-C(Me)=C(Me)Bpin}{xant(PiPr2)2} (3), have been isolated and fully characterized. The key step for the formation of the diborylalkene is the transformation of 2 into 3 as a result of the Z-E isomerization of the ß-borylalkenyl group, which takes place via metallacyclopropene intermediates. The isomerization is sterically controlled, and the pincer diphosphine adapts its coordination mode to the requirements of the process happening to act as ¿2-P, P. The Z-E isomerization of the ß-borylalkenyl ligand of 2 is slower than the oxidative addition of the diborane to 1. As a consequence, under catalytic conditions, the formation of the syn-addition product (Z)-pinBC(Me)=C(Me)Bpin is favored, although the intermediate Rh(Bpin)3{xant(PiPr2)2} is much less stable than 2.

Published
2019

24. Systematic quality assurance of the BSD2000-3D MR-compatible hyperthermia applicator performance using MR temperature imaging

Author

Mulder, H.T. (Hendrik Thijmen), Curto, S. (Sergio), Paulides, M.M. (Maarten), Franckena, M. (Martine), Rhoon, G.C. (Gerard) van, Mulder, H.T. (Hendrik Thijmen), Curto, S. (Sergio), Paulides, M.M. (Maarten), Franckena, M. (Martine), and Rhoon, G.C. (Gerard) van

Abstract

Background: Radiofrequency (RF) mild hyperthermia (40 °C–44 °C for 60 minutes) is an effective adjuvant treatment for several types of cancer. To ensure treatment efficacy, quality assurance (QA) is necessary. This study presents the first systematic 3D characterisation of the heating performance of the commonly used Pyrexar BSD2000-3D MR-compatible hyperthermia applicator using magnetic resonance temperature imaging (MRTI). Methods: A reproducibly positioned phantom was heated with a power of 1000 watts during the 12.4 min needed to measure eight temperature distributions using MRTI. The target heating location was systematically varied between experiments. We analysed focus shape characteristics, steering accuracy, focus deformation due to steering, presence of off-target heating and reproducibility. Results: The mean maximum temperature increase was 5.9 ± 0.4 °C. The mean full width half maximum (FWHM) was 14.4 ± 0.5 cm in the XY plane and 24.5 ± 0.8 cm in Z-direction. The mean steering error was 0.4 ± 0.2 cm. The focus shape slightly varied between experiments, depending on steering distance in Y-direction. Off-target heating was not detected. Reproducibility of the focus amplitude and shape was determined by comparing the mean deviation from the mean temperature in the central slice was 0.3 ± 0.2 °C. Conclusion: The Pyrexar BSD2000-3D MR-compatible applicator provides robust and reproducible heating. The upper boundary of the 95% confidence interval of the spatial steering accuracy is 0.9 cm, i.e. sufficient to fulfil the criterion of ≤0.2 °C temperature variation due to positioning errors as defined by Canters et al.

Published
2018
Full Text
View/download PDF

25. Quality assurance guidelines for superficial hyperthermia clinical trials: II. Technical requirements for heating devices

Author

Dobšíček Trefná, H. (Hana), Crezee, J., Schmidt, M. (Manfred), Marder, D., Lamprecht, U. (Ulf), Ehmann, M. (Michael), Nadobny, J. (Jacek), Hartmann, J. (Josefin), Lomax, N. (Nicoletta), Abdel-Rahman, S. (Sultan), Curto, S. (Sergio), Bakker, A. (Akke), Hurwitz, M.D. (Mark D.), Diederich, S. (Sven), Stauffer, J.C., Rhoon, G.C. (Gerard) van, Dobšíček Trefná, H. (Hana), Crezee, J., Schmidt, M. (Manfred), Marder, D., Lamprecht, U. (Ulf), Ehmann, M. (Michael), Nadobny, J. (Jacek), Hartmann, J. (Josefin), Lomax, N. (Nicoletta), Abdel-Rahman, S. (Sultan), Curto, S. (Sergio), Bakker, A. (Akke), Hurwitz, M.D. (Mark D.), Diederich, S. (Sven), Stauffer, J.C., and Rhoon, G.C. (Gerard) van

Abstract

Quality assurance (QA) guidelines are essential to provide uniform execution of clinical trials with uniform quality hyperthermia treatments. This document outlines the requirements for appropriate QA of all current superficial heating equipment including electromagnetic (radiative and capacitive), ultrasound, and infrared heating techniques. Detailed instructions are provided how to characterize and document the performance of these hyperthermia applicators in order to apply reproducible hyperthermia treatments of uniform high quality. Earlier documents used specific absorption rate (SAR) to define and characterize applicator performance. In these QA guidelines, temperature rise is the leading parameter for characterization of applicator performance. The intention of this approach is that characterization can be achieved with affordable equipment and easy-to-implement procedures. These characteristics are essential to establish for each individual applicator the specific maximum size and depth of tumors that can be heated adequately. The guidelines in this document are supplemented with a second set of guidelines focusing on the clinical application. Both sets of guidelines were developed by the European Society for Hyperthermic Oncology (ESHO) Technical Committee with participation of senior Society of Thermal Medicine (STM) members and members of the Atzelsberg Circle.

Published
2017
Full Text
View/download PDF

26. Albumin replacement in patients with severe sepsis or septic shock

Author

Gattinoni L, Caironi P, Pesenti A, Fumagalli R, Tognoni G, Romero M, Latini R, Masson S, Vincent JL, Suter PM, Valsecchi MG, Santosuosso A, Cavana M, Ortu A, Gabini R, Perno S, Anelli A, Amoruso R, Ferraris S, Borelli M, Massei R, Riva I, Poli G, Papagni G, Bortone F, Mamprin F, Keim R, Brivio M, Colageo U, Mimii EP, Sangiorgi G, Siniscalchi A, Pierucci E, Giovannitti A, Gentile C, Pascucci F, Antonini B, Zummo U, Valsecchi R, Cerisara M, Trezzi T, Dossena A, Ribola A, Tamayo L, Zoppellari R, Volta CA, Mangani V, Fanfani E, Chelazzi C, Bartoli T, Parrini V, Oggioni R, Fedele A, Molin A, Berri C, Guarino A, Isetta M, Bonfiglio M, Tissino F, Silvestri L, Milanesi M, Sbrana G, Motta E, Iannaco I, Casadio MC, Pasetti GS, Palandini A, Cascione C, Puscio D, Cellai F, Boccalatte D, Silvestri S, Fausto CI, Lupo V, Zompanti V, Iacobone E, Gattari D, Ronzoni G, Beck E, Francesconi S, Colombo R, Raimondi F, Castelli A, De Gasperi A, Radrizzani D, Ferla LE, Giudici R, Bellato V, Bordone G, Gavazzeni V, Lesmo A, Ripamonti D, Vesconi S, Papoff A, Rossi A, Noto A, Pezzi A, Zanforlin G, Kandil H, Ballotta A, Bettini F, Vaghi GM, Rossi S, Pessina C, Casagrande D, Trivellato A, Costagli V, Moise G, Furla M, Marelli S, Caspani L, Panigada M, Bruzzone P, Isgrò S, Abbruzzese C, Tagliabue P, Solca M, Bonazzi M, Cattaneo A, Rossi N, Andreoni P, Pasetto A, Girardis M, Barbieri E, Piazza O, Zagara G, Bono M, Galzerano A, Garzilli T, Dentini N, Bindi M, Biancofiore G, Mercante WP, Disconzi MM, Todesco N, Lunardi S, Sani E, Carli M, Bracciotti G, Gori V, Braccini P, Maggio G, Braschi A, Bottazzi A, Iotti G, Nicora B, Salati G, Salsi P, Antonelli M, Pennisi MA, Bello G, Caccese R, D'Ambrosio M, Rocco M, Sanseverino M, Gatta A, Nastasi M, Corsi A, Facondini F, Franchi F, Mongelli P, Ferrario M, Carulli F, Del Curto S, Schiappacasse G, Dalpiaz C, Armani S, Verderosa I, Marzullo A, Tonetti F, De Piero ME, Livigni S, Fiore G, Cerutti A, Erbetta S, Napolitano R, Pastorelli M, Bona F, Debernardi F, Gallo M, Segala V, Parigi L, Perzolla D, Marson F, Chiarandini P, Cammarano C, Sermann G, De Lucia S, Frigerio A, Distaso F, Franco R, Bossi E, Laudi C, De Nardin M, Violo T, Lazzari F, Vestali A, Della Mora E, Polati E, Martini A, Cristallini S, Totaro C, Milan B, Dan M, Ruberti S, Danzi V., GIARRATANO, Antonino, RAINERI, Santi Maurizio, CORTEGIANI, Andrea, Caironi, P, Tognoni, G, Masson, S, Fumagalli, R, Pesenti, A, Romero, M, Fanizza, C, Caspani, L, Faenza, S, Grasselli, G, Iapichino, G, Antonelli, M, Parrini, V, Fiore, G, Latini, R, Gattinoni, L, Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L, Vincent JL, Suter PM, Valsecchi MG, Santosuosso A, Cavana M, Ortu A, Gabini R, Perno S, Anelli A, Amoruso R, Ferraris S, Borelli M, Massei R, Riva I, Poli G, Papagni G, Bortone F, Mamprin F, Keim R, Brivio M, Colageo U, Mimii EP, Sangiorgi G, Siniscalchi A, Pierucci E, Giovannitti A, Gentile C, Pascucci F, Antonini B, Zummo U, Valsecchi R, Cerisara M, Trezzi T, Dossena A, Ribola A, Tamayo L, Zoppellari R, Volta CA, Mangani V, Fanfani E, Chelazzi C, Bartoli T, Oggioni R, Fedele A, Molin A, Berri C, Guarino A, Isetta M, Bonfiglio M, Tissino F, Silvestri L, Milanesi M, Sbrana G, Motta E, Iannaco I, Casadio MC, Pasetti GS, Palandini A, Cascione C, Puscio D, Cellai F, Boccalatte D, Silvestri S, Fausto CI, Lupo V, Zompanti V, Iacobone E, Gattari D, Ronzoni G, Beck E, Francesconi S, Colombo R, Raimondi F, Castelli A, De Gasperi A, Radrizzani D, Ferla LE, Giudici R, Bellato V, Bordone G, Gavazzeni V, Lesmo A, Ripamonti D, Vesconi S, Papoff A, Rossi A, Noto A, Pezzi A, Zanforlin G, Kandil H, Ballotta A, Bettini F, Vaghi GM, Rossi S, Pessina C, Casagrande D, Trivellato A, Costagli V, Moise G, Furla M, Marelli S, Panigada M, Bruzzone P, Isgrò S, Abbruzzese C, Tagliabue P, Solca M, Bonazzi M, Cattaneo A, Rossi N, Andreoni P, Pasetto A, Girardis M, Barbieri E, Piazza O, Giarratano A, Raineri SM, Cortegiani A, Zagara G, Bono M, Galzerano A, Garzilli T, Dentini N, Bindi M, Biancofiore G, Mercante WP, Disconzi MM, Todesco N, Lunardi S, Sani E, Carli M, Bracciotti G, Gori V, Braccini P, Maggio G, Braschi A, Bottazzi A, Iotti G, Nicora B, Salati G, Salsi P, Pennisi MA, Bello G, Caccese R, D'Ambrosio M, Rocco M, Sanseverino M, Gatta A, Nastasi M, Corsi A, Facondini F, Franchi F, Mongelli P, Ferrario M, Carulli F, Del Curto S, Schiappacasse G, Dalpiaz C, Armani S, Verderosa I, Marzullo A, Tonetti F, De Piero ME, Livigni S, Cerutti A, Erbetta S, Napolitano R, Pastorelli M, Bona F, Debernardi F, Gallo M, Segala V, Parigi L, Perzolla D, Marson F, Chiarandini P, Cammarano C, Sermann G, De Lucia S, Frigerio A, Distaso F, Franco R, Bossi E, Laudi C, De Nardin M, Violo T, Lazzari F, Vestali A, Della Mora E, Polati E, Martini A, Cristallini S, Totaro C, Milan B, Dan M, Ruberti S, and Danzi V

Subjects
Male, medicine.medical_specialty, ALBUMIN, SEPSIS, SEVERE SEPSIS, SEPTIC SHOCK, Sepsi, Serum albumin, Settore MED/41 - Anestesiologia, Aged, Albumins, Female, Humans, Isotonic Solutions, Middle Aged, Rehydration Solutions, Sepsis, Serum Albumin, Shock, Septic, Survival Rate, Treatment Outcome, Intensive care, medicine, albumin replacement, Survival rate, Isotonic Solution, Medicine (all), SEPSIS, biology, business.industry, Septic shock, Rehydration Solution, Septic, Albumin, SEPTIC SHOCK, Organ dysfunction, Shock, General Medicine, medicine.disease, Surgery, Anesthesia, Relative risk, biology.protein, medicine.symptom, business, Human
Abstract

BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. RESULTS: During the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P

Published
2014

36. Le sostanze fenoliche

Author

Dugo, Giacomo, Leuzzi, Ugo, Curto, S. LO, Saitta, Marcello, and Abrami, F.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results